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Abstract
Background: This study investigated the pharmacokinetics of fosmidomycin when given in combination with clindamycin at
two dosage regimens in patients with acute uncomplicated falciparum malaria.
Methods: A total of 70 patients with acute uncomplicated Plasmodium falciparum malaria who fulfilled the enrolment criteria
were recruited in the pharmacokinetic study. Patients were treated with two different dosage regimens of fosmidomycin in
combination with clindamycin as follows:
Group I: fosmidomycin (900 mg) and clindamycin (300 mg) every 6 hours for 3 days (n = 25); and Group II: fosmidomycin (1,800
mg) and clindamycin (600 mg) every 12 hours for 3 days (n = 54).
Results: Both regimens were well tolerated with no serious adverse events. The 28-day cure rates for Group I and Group II
were 91.3 and 89.7%, respectively. Steady-state plasma concentrations of fosmidomycin and clindamycin were attained at about
24 hr after the first dose. The pharmacokinetics of both fosmidomycin and clindamycin analysed by model-independent and
model-dependent approaches were generally in broad agreement. There were marked differences in the pharmacokinetic
profiles of fosmidomycin and clindamycin when given as two different combination regimens. In general, most of the dose-
dependent pharmacokinetic parameters (model-independent Cmax: 3.74 vs 2.41 μg/ml; Cmax-ss: 2.80 vs 2.08 μg/ml; Cmax-min-ss: 2.03
vs 0.71 μg/ml; AUC: 23.31 vs 10.63 μg.hr/ml (median values) were significantly higher in patients who received the high dose
regimen (Group II). However, Cmin-ss was lower in this group (0.80 vs 1.37 μg/ml), resulting in significantly higher fluctuations in
the plasma concentrations of both fosmidomycin and clindamycin following multiple dosing (110.0 vs 41.9%). Other
pharmacokinetic parameters, notably total clearance (CL/F), apparent volume of distribution (V/F, Vz/F) and elimination half-life
(t1/2z, t1/2e) were also significantly different between the two dosage regimens. In addition, the dose-dependent pharmacokinetics
of both fosmidomycin and clindamycin tended to be lower in patients with recrudescence responses in both groups.
Conclusion:  The findings may suggest that dosing frequency and duration have a significant impact on outcome. The
combination of fosmidomycin (900 mg) and clindamycin (300–600 mg) administered every six hours for a minimum of five days
would constitute the lowest dose regimen with the shortest duration of treatment and which could result in a cure rate greater
than 95%.
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Background
The increasing devastation of malarial infections is cur-
rently responsible for hundreds of millions of clinical
cases and several million deaths annually [1]. The Plasmo-
dium falciparum parasite causing the disease is now
becoming highly resistant to a wide variety of anti-malar-
ial drugs including chloroquine and the sulphadoxine/
pyrimethamine combination [1]. This underscores the
urgent requirement for new effective and safe anti-malar-
ial drugs with novel modes of action for the treatment of
multidrug resistant P. falciparum malaria.
Fosmidomycin has been shown to be an effective blood
schizonticide in addition to its wide spectrum of antibac-
terial activity. It possesses a novel mode of action through
inhibition of 1-deoxy-D-xylulose  5-phosphate (DOXP)
reductoisomerase, an essential enzyme of the non-meval-
onate pathway. This occurs in the organelles of the para-
sites, the apicoplasts, where it selectively blocks the
biosynthesis of isopentenyl diphosphate and the subse-
quent development of isoprenoids in P. falciparum [2-5].
The drug possesses potent anti-malarial activity both in
vitro and in vivo. However, in the treatment of clinical
malaria, the high rate of recrudescent infections precludes
its use as monotherapy [6]. The combination of fosmid-
omycin with clindamycin emerged as a potential anti-
malarial treatment on the basis of in vitro and in vivo syn-
ergistic activity [7,8] and the outcome of subsequent clin-
ical studies in Gabonese children [9,10].
The first clinical pharmacokinetic data from studies of fos-
midomycin alone and in combination with clindamycin
have recently been documented for 33 Thai patients diag-
nosed with acute uncomplicated P. falciparum malaria
[11]. The study constituted part of two dose optimization
Phase II trials of fosmidomycin monotherapy (1,200 mg
every 8 hours for 7 days] and of combination therapy with
clindamycin (fosmidomycin: 900 mg every 12 hours for 7
days; clindamycin: 600 mg every 12 hours for 7 days]
[12,13]. Both the monotherapy and combination therapy
regimens were well tolerated and no serious adverse
events were reported. Combination therapy with fosmid-
omycin and clindamycin proved highly effective with a
100% cure rate, whereas the cure rate with the mono-
therapy regimen was only 22% during the 28-day follow
up period.
The pharmacokinetics of fosmidomycin when adminis-
tered alone and in combination with clindamycin were
similar except for the apparent volumes of distribution
(Vz/F) and total clearances (CL/F) that were significantly
lower for the combination regimen. Steady-state plasma
concentrations of fosmidomycin and clindamycin were
attained at the time of the second or third dose. There was
no evidence of dose accumulation during multiple dos-
ing. Urinary recovery of fosmidomycin was 18.7 and 20%
following monotherapy and combination therapy respec-
tively.
The present pharmacokinetic study aimed to optimize the
regimen of fosmidomycin and clindamycin when admin-
istered over three days as an effective and safe treatment
for multidrug-resistant P. falciparum malaria.
Patients and methods
Study design and patients
This pharmacokinetic study was part of an open-label,
randomized uncontrolled, dose optimization clinical trial
in 114 patients with acute uncomplicated falciparum
malaria. The study was conducted during 2006 at the two
main study sites – Bangkok (Hospital for Tropical Dis-
eases; n = 84), and Tak Province (Mae Sot General Hospi-
tal and Umphang Hospital; n = 30). The latter is located
in an area along the Thai-Myanmar border, where multid-
rug resistance exists. Approval of the study protocol was
obtained from the Ethics Committees of the Ministry of
Public Health of Thailand and the Faculty of Tropical
Medicine, Mahidol University, Bangkok. A total of 80
patients, 77 males and 3 females, of varying ethic groups
(30 Karen, 20 Burmese and 20 Thai) were included in the
pharmacokinetic study.
The age, body weight and admission parasitaemia ranges
were 15 – 61 years, 45.0 – 68.0 kg and 1,152 – 254,800
asexual parasites/μl respectively. Pre-treatment investiga-
tions consisted of clinical assessments (general medical
history, demographic data, significant medical history,
previous drug administration, physical examinations,
monitoring of vital signs and malaria signs and symp-
toms), laboratory assessments (thick and thin blood
smears for parasite identification/quantification), routine
haematology and biochemistry, urinalysis and stool
examination for parasites and ova). Most patients showed
baseline laboratory parameters outside the normal ranges,
which are common in patients with acute falciparum
malaria and all were mild or moderate in severity.
All patients were admitted to the hospitals for 7 days and
were requested to attend for follow-up visits on days 14,
21 and 28 or until suspected signs and/or symptoms of
malaria appeared.
Drug administration
This study was planned as a proof-of-concept study to
investigate the combination regimen of fosmidomycin-
clindamycin that would produce approaching 100% cure
rate with short duration of 3 days and less frequent dosing
interval. The design of dosage regimens used in the
present study was based on background information from
previous studies [11-13]. The total number of patientsMalaria Journal 2008, 7:225 http://www.malariajournal.com/content/7/1/225
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recruited for Group I and II was at the ratio of approxi-
mately 1: 3.5 (25 vs 89 cases, respectively). Patients from
each study site were sequentially entered into the study
and treated with one of two different combination regi-
mens of fosmidomycin and clindamycin as follows:
Group I (n = 25): fosmidomycin sodium capsules
(Alphamed PHARBIL Arzneimittel GmbH, Germany) 450
mg × 2 tablets, six-hourly for 3 days plus clindamycin
hydrochloride capsules (Alphamed PHARBIL Arzneimit-
tel GmbH, Germany) 150 mg × 2 tablets, six-hourly for 3
days; and Group II (n = 89): fosmidomycin sodium cap-
sules 450 mg × 4 tablets, twelve-hourly for 3 days plus
clindamycin hydrochloride capsules 150 mg × 4 tablets,
twelve-hourly for 3 days.
The patients fasted overnight (8–10 hr) and emptied their
bladders immediately before drug administration. The
drugs were administered orally with 250 ml of water and
a standard hospital meal (20–25% fat content) under
supervision of the assigned study staff. After ingestion of
the medication, patients were observed for 1 hr and in the
event of vomiting, the medication was re-administered.
Meals were provided at 4 hr post-dosing. Fruit juice and
water were freely available throughout the period of hos-
pitalization. The administration of prescription drugs,
deemed necessary for the well-being of the patients, were
permitted during the study period and documented.
Blood and urine collection
Pharmacokinetic investigation was performed in all (n =
25) patients in Group I, while only 54 cases in Group II
from both study sites were randomly recruited for phar-
macokinetic investigation. Blood samples (4 ml) were
obtained at the following time points:- Group I: 0, 1, 2, 3,
4, 6, 8, 12, 18, 24, 26, 30, 36, 42, 48, 50, 54, 60, 66, 72
and 74 hours from the commencement of dosing; Group
II: 0, 1, 2, 3, 4, 6,12, 14,24, 26, 36, 38, 48, 50, 60, 62, 72
and 74 hours from the commencement of dosing. Blood
samples were drawn via an indwelling venous cannula
and collected in heparinized tubes. Where appropriate,
blood samples were taken immediately prior to the next
dose. Immediately after collection, the tubes were centri-
fuged (2,000 g) for 10 minutes. The plasma samples were
stored at -80°C pending analysis.
Twelve hourly urine collections were made during the first
four days as follows: 0–12, 13–24, 25–36, 37–48, 49–60,
61–72, 73–84 and 85–96 hours. The total volume of each
collection was recorded. A 20 ml aliquot was taken from
each collection and stored at -80°C until analysis.
Efficacy assessment
Efficacy assessments included clinical and parasitological
evaluations. Clinical signs/symptoms of malaria includ-
ing body temperature were monitored on days 0, 1, 2, 3,
4, 5, 6, 7, 14, 21 and 28. Finger-prick blood smears were
examined at 6 hourly intervals until three consecutive
negative readings were obtained, then once daily during
hospitalization, and then on days 14, 21 and 28. The films
were stained with Giemsa and parasite counts were deter-
mined by counting the number of asexual parasites per
1,000 red blood cells on a thin film or per 200 white
blood cells on a thick film. The protocol used to deter-
mine the response to treatment was adapted from the
World Health Organization [14]. Efficacy was assessed
using the following criteria: (i) polymerase chain reaction
(PCR)-adjusted 28 day cure rate:- the proportion of
patients with clearance of asexual parasitaemia within 7
days of the commencement of treatment and without sub-
sequent recrudescence during the 28 day follow-up
period: (ii) parasite clearance time (PCT):- as calculated
from the commencement of therapy to the time of the first
negative film for asexual parasites subject to two consecu-
tive films remaining negative: (iii) fever clearance time
(FCT):- as calculated from the commencement of therapy
to the time that the temperature falls below 37.5°C and
remains below 37.5°C for 48 hours.
Safety and tolerability assessment
Safety and tolerability were assessed on the clinical find-
ings and abnormal laboratory tests (routine haematology
and biochemistry) that first occur or increase in severity
during the study period in accordance with the Common
Toxicity Criteria CTC grade [15].
Drug analysis
Fosmidomycin concentrations in plasma and urine were
determined by a bioassay system based on agar disk diffu-
sion using Enterobacter cloacae ATCC 23355 as the test
organism [16]. The precision of the assay method was
examined and the within-day (repeatability) and day-to-
day (reproducibility) variations were below 5% (% coeffi-
cient of variation: % C.V.). Good accuracy was also
observed for both the intra-day and inter-day assays. The
limit of quantification was 1 ng using 40 μl of plasma or
7.5 μl of urine.
Plasma concentrations of clindamycin were measured by
high performance liquid chromatography as described
previously [17]. The precision of the method within-day
and day-to-day variations were below 15% (% C.V.) Good
accuracy was observed for both the intra-day and inter-
day assays, as indicated by the minimal deviation of mean
values found with measured samples compared to theo-
retical values (below ± 15%). The limitation of quantifica-
tion was considered acceptable at 0.07 μg, using plasma
sample quantities of 1 ml.Malaria Journal 2008, 7:225 http://www.malariajournal.com/content/7/1/225
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Pharmacokinetic analysis
The non-compartmental pharmacokinetic analysis was
used to determine the pharmacokinetic parameters of fos-
midomycin and clindamycin after a single initial dose of
the two drugs [18]. Cmax was defined as the maximum
plasma concentrations and tmax was the time required to
reach maximum plasma concentrations following a single
initial dose or the final dose. Cmin-obs was the observed
trough concentration. The area under the concentration-
time curve from the zero time point to the last sampling
point yielding a quantifiable concentration (AUC0, t) was
calculated with the log-linear trapezoidal method. A min-
imum of three final sampling points were used to deter-
mine the first order constants generated by the terminal
portion of the curve (λz). Terminal phase elimination
half-life (t1/2z) was defined as t1/2z = ln(2)/λz. The AUC
from time zero to infinity (AUC) was calculated as AUC0-
t + Ct/λz, where Ct stands for the last measurable concen-
tration. Total clearances (CL/F) were calculated from
Dose/AUC0,8 and apparent volumes of distribution (Vz/F)
were calculated as CL/F/λz, where F is bioavailability. The
maximum plasma concentrations at steady-state (Cmax-ss),
minimum plasma concentrations at steady-state (Cmin-ss)
and average plasma concentrations at steady-state (Cave-ss)
following a fast release oral formulation could all esti-
mated using:
Cmin-ss = Cmax-ss ·e-λ.τ
Where τ is the dosing interval (hr).
Fluctuations between Cmax-ss and Cmin-ss were calculated
from the ratio between the two parameters.
For the purpose of future stimulation and prediction as
well as pharmacokinetic/pharmacodynamic modelling,
the compartment open model (one- or two-) with first-
order absorption and elimination with absorption lag
time was fitted to the data by iterative, weighted non-lin-
ear regression using ADAPT II (release 4.0) [19]. The
observed concentrations of fosmidomycin and clindamy-
cin were weighted as the reciprocal of the analytical vari-
ance. Data reported in the previous study [11] were used
for the initial estimation of the pharmacokinetic parame-
ters. The adequacy of the pharmacokinetic models chosen
was based on statistical methods for assessing the validity
of the models for describing the concentration-time data,
i.e., F-ratio test, Akaike information criterion (AIC),
Schwartz and Imbimbo criteria.
Total urinary excretion of fosmidomycin was calculated
from the sum of amounts of drug excreted during each 12-
hour interval multiplied by total urine volume at each
interval. The dose excreted (%) was calculated from total
amounts of drug excreted in urine during 72 hours
divided by total dose given.
Statistical analysis
Descriptive statistics were calculated for the pharmacoki-
netic variables. Geometric means were determined for
baseline parasite counts. All pharmacokinetic parameters
were presented as median values (95% C.I.). Compari-
sons of the pharmacokinetic parameters between the two
groups were performed using the Mann-Whitney U test.
The level of statistical significance was set at α = 0.05 for
all tests.
Results
A total of 25 (Group I) and 89 (Group II) patients received
treatment with the two different combination regimens of
fosmidomycin and clindamycin. Most patients had base-
line laboratory parameters (haematology and serum bio-
chemistry) outside the normal ranges; most are common
in patients with acute falciparum malaria and all were
mild or moderate in severity. For Group I, one case was
withdrawn after eight doses due to hyperpyrexia; one case
was excluded for efficacy analysis due to appearance of P.
vivax in peripheral blood smear. Two cases had reappear-
ance of P. falciparum in their blood smears on day 28 and
both were confirmed by PCR as recrudesced parasites. For
Group II, three cases were withdrawn (one case after two
doses due to allergy, one case each after four and five
doses due to diarrhoea; eight cases were excluded for effi-
cacy analysis due to appearance of P. vivax in peripheral
blood smear (two cases on day 14, one case on day 20 and
five cases on day 21). Seven cases had reappearance of P.
falciparum in their blood smears during days 21–28 and
all but one was confirmed by PCR as recrudesced para-
sites. PCR-adjusted cure rates on day 28 for Group I and II
were 91.3% (21/23) and 89.7% (70/78) respectively. Kap-
lan-Meier curve of PCR-adjusted cumulative treatment
failure over the 28-day follow-up period is shown in Fig-
ure 1.
FCTs and PCTs [median values] were 40 (4–76) and 50
(20–80) hours respectively. Concomitant medication
included paracetamol, dimenhydinate, diphenhydramine
and chlorpheniramime. Both combination regimens were
well tolerated with no serious adverse events. Gastro-
intestinal symptoms were the most commonly reported
adverse experiences with abdominal pain developing in
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Pharmacokinetics and urinary excretion
The concentration-time data of both fosmidomycin and
clindamycin were in all cases best fitted with one-com-
partment open model with first-order absorption and
elimination. Observed and model-predicted (one-com-
partment model with first-order absorption and elimina-
tion with absorption lag time) median plasma
concentrations of fosmidomycin and clindamycin in
patients with sensitive responses following implementa-
tion of the two combination regimens are shown in Fig-
ures 2 and 3, respectively. The pharmacokinetic
parameters of both drugs analysed by model-independent
and model-dependent methods are summarized in Table
1 and 2 respectively. Variability as expressed as % C.V. for
all parameters varied between 7.7 and 40.5% for fosmid-
omycin and 12.2 and 38.9% for clindamycin. Results
obtained from model-dependent analysis for both fosmi-
domycin and clindamycin were generally in agreement
with those obtained from model-independent analysis.
Fluctuation was significantly higher (260% for fosmid-
omycin and 120% for clindamycin) following the admin-
istration of the high dose combination regimen.
Fosmidomycin
All of the dose-dependent pharmacokinetic parameters
including Cmax, Cmax-ss, Cmax-min-ss and AUC were signifi-
cantly higher in Group II than for Group I (160, 120, 240
and 162% of that in Group I respectively). On the other
hand, Cmin-ss was significantly lower in Group-II com-
pared to Group I. Furthermore, total clearances (CL/F)
and volumes of distribution (V/F, Vz/F) were found to be
significantly greater and t1/2e was significantly longer in
Group II patients with all values being 120%. Total uri-
nary excretion of fosmidomycin and the % dose excreted
in Group II were about 68% of Group I: however a statis-
tically significant difference was only observed with the %
dose excreted.
Clindamycin
All dose-dependent pharmacokinetic parameters includ-
ing Cmax, Cmax-ss, Cmax-min-ss, Cave-ss and AUC were signifi-
cantly higher in Group II compared with Group I (150,
152, 210 and 240% of those in Group I respectively). In
addition, V/F values were significantly larger (210%) and
t1/2e longer (390%) in Group II patients. Moreover, Vz/F
and t1/2e were found to be significantly higher in Group II
(210 and 390%, respectively).
Relationship between plasma drug concentration and 
therapeutic outcome
Fosmidomycin
Based on the model-independent approach, all the dose-
dependent parameters in Group II were lower in patients
with recrudescent infections (n = 9) compared with those
who were cured (n = 45), but statistically significant dif-
ferences were observed only with Cmax, AUC, Cave-ss and
Cmax-min-ss (50, 60, 80 and 60%, respectively) in patients
who recrudesced compared to those who were cured. In
addition, CL/F was significantly higher (210%) in recru-
descent patients.
Kaplan-Meier curve of PCR-adjusted cumulative treatment failure over the 28-day follow-up period Figure 1
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Observed and predicted plasma concentration-time profiles (median values) of fosmidomycin in patients with sensitive  responses in Group-I (fosmidomycin 900 mg plus 300 clindamycin every 6 hours for 3 days; N = 23) and Group-II (fosmidomy- cin 1800 mg plus 600 mg clindamycin every 12 hours; N = 45) Figure 2
Observed and predicted plasma concentration-time profiles (median values) of fosmidomycin in patients with 
sensitive responses in Group-I (fosmidomycin 900 mg plus 300 clindamycin every 6 hours for 3 days; N = 23) 
and Group-II (fosmidomycin 1800 mg plus 600 mg clindamycin every 12 hours; N = 45). The curve represents sim-
ulated concentration-time profile based on the median concentrations in each group.
Group-I 
        
        
     
        
            
     
         
  
    
              
  
 
     





    
        







       
       
   
   
       
   
             
    
  
  
     
       
     
Group-II 
     
        
        
        
                 
   
      
       
       
        
        
   
       
   
       
         
       
           
       
       
   
   
   
      
    
    
       
   
  

   
Malaria Journal 2008, 7:225 http://www.malariajournal.com/content/7/1/225
Page 7 of 11
(page number not for citation purposes)
Observed and predicted plasma concentration-time profiles (median values) of clindamycin in patients with sensitive response  in Group-I (fosmidomycin 900 mg plus 300 clindamycin every 6 hours for 3 days) and Group-II (fosmidomycin 1800 mg plus  600 mg clindamycin every 12 hours) Figure 3
Observed and predicted plasma concentration-time profiles (median values) of clindamycin in patients with 
sensitive response in Group-I (fosmidomycin 900 mg plus 300 clindamycin every 6 hours for 3 days) and 
Group-II (fosmidomycin 1800 mg plus 600 mg clindamycin every 12 hours). The curve represents simulated concen-
tration-time profile based on the median concentrations in each group.
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Clindamycin
One of the two patients who recrudesced in Group I had
markedly lower plasma levels (AUC 24.94 μ.hr/ml, Cmax
5.61 μ/ml, Cmax-ss 5.06 μ/ml, Cmin-ss 1.71 μ/ml), whereas
another had markedly higher values for all of the dose-
dependent pharmacokinetic parameters (AUC 4.52 μ.hr/
ml, 2-hour concentration 0.68 μg/ml, Cmax 1.12 μg/ml,
Cmax-ss 0.98 μg/ml, Cmin-ss 0.54 μg/ml, Cave-ss 0.77 μg/ml)
when compared with the median values observed in the
sensitive group. However, all of the dose-dependent
parameters were lower in the Group II patients who recru-
desced including Cave-ss, but statistically significant differ-
ences were only observed with Cmax, Cmax-ss and Cmin-ss
(120, 150 and 140%, respectively) in patients with recru-
descent infections compared with those who were cured.
In addition, CL/F was significantly higher (210%). Fluctu-
ation appeared to be higher (113%) in the group with
recrudescence responses.
Discussion
In the present study, the pharmacokinetic parameters of
fosmidomycin and clindamycin which were obtained
from model dependent and model-independent analysis
were generally in broad agreement and with our recent
investigation following the lower dose regimen (900 mg
fosmidomycin plus 600 mg clindamycin given every 12
hours over 12 hours) [11]. Due to the marked variation in
the model-fitted data, statistically significant differences
between the two dosage regimens (Group I vs Group II
and sensitive vs recrudescence responses) for some of the
parameters was not observed. The dose-dependent phar-
macokinetic parameters (elimination half-life, clearance,
volume of distribution) for both fosmidomycin and clin-
damycin were similar with that reported in the previous
study [11]. However, the dose-dependent pharmacoki-
netic parameters (Cmax, Cmax-ss, Cmin-ss and Cave-ss) of fos-
midomycin observed in this study were markedly lower
than that observed in the previous study even with twice
as high dose of fosmidomycin (1,800 mg) was adminis-
tered. Cave was only about 60 μg/ml in Group I patients in
current study who received the same dose of 900 mg fos-
midomycin. When comparing between Group I and
Group II in the present study, almost all of the dose-
dependent pharmacokinetic parameters of fosmidomycin
and clindamycin (Cmax, Cmax-ss, Cmin-ss, Cave-ss, AUC) were
significantly higher in the high dose Group II regimen
showing varying degrees of elevation ranging from 120 to
280%. Since Cmin-ss was lower in the high dose group, fluc-
tuation (%) was also greater in the high dose regimen. In
addition, the dose-independent pharmacokinetic param-
eters, i.e., CL/F, Vz/F and t1/2z or t1/2e were significantly
greater in this group. The extent of the changes in these
pharmacokinetic parameters was more pronounced with
fosmidomycin than with clindamycin. These findings sug-
Table 1: Pharmacokinetics of fosmidomycin analysed by model-independent and model-dependent approach in patients with sensitive 
responses in Group-I and II.









tmax (hr) 2.0 (1.0–4.0) 3.0 (1.0–6.0) 2.6 (1.0–3.8)a 3.2 (0.8–4.3)
tlag (hr) NA NA 0.3 (0.001–0.8) 0.55 (0.001–1.6)
K01 (/hr) NA NA 0.35 (0.15–3.00) 0.56 (0.09–4.00)
t1/2a (hr) NA NA 2.0 (0.2–8.0) 1.97 (0.1–7.7)
Cmax (μg/ml) 2.41 (0.91–16.23)b 3.74(1.49–8.94) 1.77 (0.96–2.97)c 2.92 (1.40–6.93)
AUC (μg.hr/ml) 10.63 (4.27–53.85) 23.31 (11.42–66.13) 13.30 (6.89–24.33)d 26.18 (14.72–54.49)
K10 (/hr) NA NA 0.37 (0.09–1.92) 0.36 (0.08–2.00)
t1/2z (hr) 3.5 (0.8–14.9)e 4.2 (2.1–7.9) NA NA
t1/2e (hr) NA NA 1.6 (0.2–5.3)f 2.2 (0.3–8.2)
CL/F (l/hr) 47.51 (16.46)g 57.69 (9.29–132.54) 67.62 (23.39–130.57) 68.27 (33.03–122.31)
Vz/F (l) 272.64 (20.22–702.25)h 338.56 (131.65–895.17) NA NA
V/F (l) NA NA 194.50 (34.17–855.40) 174.11 (30.23–924.62)
Cmin-ss (μg/ml) 1.37 (1.08–5.09)i 0.80 (0.20–2.11) 1.62 (0.66–2.69)j 0.97 (0.20–2.25)
Cmax-ss (μg/ml) 2.28 (1.34–9.43)k 2.80 (1.18–6.52) 2.63 (1.46–4.64)l 3.26 (1.83–7.27)
Cave-ss (μg/ml) 1.77 (0.71–8.98) 1.94 (0.95–5.51) 2.22(1.45–4.06) 2.18(0.51–4.54)
Cmax-min-ss (μg/ml) 0.71 (0.05–4.34)m 2.03 (0.59–5.41) 1.11 (0.39–2.23)n 2.24 (0.04–5.76)
Fluctuation (%) 41.9 (40.1–203.6)° 110.0 (30.8–223.4) 49.2 (50.8–191.5)p 118.7 (41.2–218.5)
Data are presented as median (95% CI).
NA = Not applicable
a Statistically significant difference from Group-II with p = 0.009, 95%CI = 0.9 (0.2–1.5); b p = 0.029, 95%CI = 1.45(0.77–2.04); c p < 0.0001, 95%CI = 
0.78(0.15–2.11); d p < 0.0001, 95%CI = 15.99(4.15–26.77); e p = 0.022, 95%CI = 0.8(0.4–6.5),;f p < 0.0001, 95%CI = 0.2(0.09–0.9); g p = 0.006, 95%CI 
= 14.77(6.11–122.14); h p = 0.0001, 95%CI = 76.66(33.48–48.77); i p = 0.0001, 95%CI = 0.78(0.34–2.25); j p < 0.0001, 95%CI = 0.32(0.11–1.02); k p 
= 0.048, 95%CI = 0.45(0.20–0.79); l p ≤ 0.0001, 95%CI = 0.98(0.45–1.45); m p = 0.033, 95%CI = 0.64(0.23–1.78); n p = 0.039, 95%CI = 0.67(0.23–
1.12); ° p = 0.001, 95%CI-65.8(23.1–102.3); p p = 0.0001, 95%CI = 62.1(24.6–123.6) (Mann-Whitney U-test)Malaria Journal 2008, 7:225 http://www.malariajournal.com/content/7/1/225
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gest that saturation in some of the pharmacokinetic proc-
esses for fosmidomycin occurred particularly with respect
to elimination as renal clearance is the major route of drug
elimination. This supposition is supported by the urinary
excretion data which shows that the total urinary excre-
tion of fosmidomycin was approximately 50% in Group
II compared with Group I.
There was a relationship between plasma drug concentra-
tions and therapeutic outcome since the dose-dependent
pharmacokinetic parameters of fosmidomycin and clin-
damycin were significantly lower in the group of patients
with recrudescence responses, particular in Group II
patients. The extent of the differences in these pharmacok-
inetic parameters was more pronounced for fosmidomy-
cin. Together, clinical efficacy and pharmacokinetics of
fosmidomycin and clindamycin observed in the present
study and in previous studies [11,13] suggest that the
combination of fosmidomycin with fosmidomycin may
provide an alternative treatment for multidrug resistant
uncomplicated Plasmodium falciparum malaria in prefer-
ence to the combination of artesunate/mefloquine. There
has not been any prior evidence for cross resistance
between fosmidomycin and other anti-malarials. Clin-
damycin is the most appropriate combination partner.In
vitro studies in our laboratory confirm the pronounced
antagonistic effect of fosmidomycin and the artemisinin
derivatives [20]. Three dose regimens of this combination
have been investigated for their efficacy and pharmacoki-
netics in studies Thailand. The first combination regimen
of fosmidomycin (900 mg every 12 hr for seven days) plus
clindamycin (600 mg every 12 hr for seven days) resulted
in a 28-day cure rate of 100% [11,13]. In the present
study, the combination of fosmidomycin (900 mg every 6
hr for 3 days vs 1800 mg every 12 hr for 3 days) plus clin-
damycin (300 mg every 6 hr for 3 days vs 600 mg every 12
hr for 3 days) resulted in a 28-day cure rates of 91.3 vs
89.7%, respectively. Both combination regimens were
well tolerated without any sign of serious adverse events.
All of the observed adverse events were of mild or moder-
ate in severity and are commonly associated with malaria
infection. These findings may suggest that dosing fre-
quency and duration have a significant impact on out-
come. The combination of fosmidomycin (900 mg) and
clindamycin (300–600 mg) given at 6 hourly for 7 days
would be an ideal regimen, but is impractical for reasons
of compliance. Based on the observed pharmacokinetic
profiles, increasing the doses of fosmidomycin to 1800
mg and with a less frequent dosing interval of twelve
hours resulted in marked fluctuations in the trough and
peak plasma concentrations during steady-state. The
importance of optimal fosmidomycin dose regimen in
malaria treatment has been shown in the previous study
[11]. Unlike fosmidomycin, the anti-malarial action of
Table 2: Pharmacokinetics of clindamycin analysed by model-independent and model-dependent approach in patients with sensitive 
responses in Group-I and II.









tmax (hr) 2.0 (1.0–4.0) 3.0 (1.0–4.0) 2.0 (0.7–3.0) 2.4 (0.6–4.4)
tlag (hr) NA NA 0.44 (0.00–0.90) 0.67 (0.001–1.45)
K01 (/hr) NA NA 0.62 (0.40–4.00) 1.48 (0.11–4.00)
t1/2a (hr) NA NA 1.1 (0.1–1.7) 0.4 (0.1–6.0)
Cmax (μg/ml) 4.34 (0.89–8.23)a 6.23 (3.23–25.11) 3.70 (1.15–5.61)b 5.79 (3.38–18.11)
AUC (μg.hr/ml) 16.82 (4.07–31.46)c 39.77 (3.41–136.16) 21.13 (8.91–37.40)d 52.91 (28.81–126.73)
K10 (/hr) NA NA 0.40 (0.15–0.78) 0.18 (0.09–0.68)
t1/2z (hr) 2.7 (0.7–7.7)e 4.4 (1.8–11.5) NA NA
t1/2e (hr) NA NA 1.0 (0.8–4.7)f 3.9 (1.0–7.7)
CL/F (l/hr) 11.81 (4.70–68.56) 11.00 (2.11–332.66) 14.19 (8.02–33.68) 11.85 (4.73–42.31)
Vz/F (l) 51.99 (11.45–207.07)g 72.82 (24.94–896.94) NA NA
V/F (l) NA NA 38.12 (26.37–229.06)h 78.85 (17.85–178.04)
Cmin-ss (μg/ml) 1.99 (0.87–4.56) 1.54 (0.23–6.98) 2.24 (0.97–24.00) 1.66 (0.19–4.93)
Cmax-ss (μg/ml) 4.34 (2.10–14.00)i 7.23 (3.45–16.54) 4.80 (1.00–8.47)j 6.80 (4.10–17.77)
Cave-ss (μg/ml) 2.80 (0.68–5.24) 3.31 (0.28–11.35) 1.88 (0.74–5.09)k 4.41 (2.40–10.56)
Cmax-min-ss (μg/ml) 2.39 (0.22–9.88)l 5.78 (1.89–13.33) 2.70 (0.86–4.13)m 4.96 (2.46–14.80)
Fluctuation (%) 104.4 (5.3–188.4)n 126.2 (29.2–145.6) 98.7 (12.9–201.2)° 158.4 (35.7–159.2)
Data are presented as median (95% CI).
NA = Not applicable
a Statistically significant difference from Group-II with p < 0.0001, 95%CI = 1.56(0.80–3.70); b p < 0.0001, 95%CI = 2.01(0.88–4.10); c p = 0.0001, 
95%CI = 15.46(8.11–19.23); d p < 0.0001, 95%CI = 15.45(9.11–20.23); e p = 0.0001, 95%CI = 1.5(0.4–1.3);f p = 0.003, 95%CI = 0.8(0.4–4.3); g p = 
0.001, 95%CI = 12.65(8.77–20.23); h p = 0.001, 95%CI = 20.14(15.22–50.47); i p < 0.0001, 95%CI = 2.23(0.89–4.55); j p < 0.0001, 95%CI = 
1.56(0.89–4.55); k p < 0.0001, 95%CI = 1.12(0.44–2.36); l p = 0.007, 95%CI = 0.78(0.55–1.43); m p < 0.0001, 95%CI = 2.02(1.55–4.23); n p = 0.039, 
95%CI = 10.7(2.0–25.1); ° p < 0.0001, 95%CI= 32.2(14.1–50.8) (Mann-Whitney U-test)Malaria Journal 2008, 7:225 http://www.malariajournal.com/content/7/1/225
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fosmidomycin is time-dependent [21,22]. Since the min-
imum inhibitory concentration (MIC) of fosmidomycin
for multidrug resistant strains of P. falciparum is not
known, it would be important to maintain the MIC as
high as possible throughout at least three or four cycles of
asexual replication. Nevertheless, for the partner drug
clindamycin which its anti-malarial action is believed to
be concentration-dependent [23], this would be a major
gap in applying pharmacokinetics in designing of appro-
priate dose regimen in the combination regimen. Parasite
susceptibility to fosmidomycin (as well as clindamycin) is
an important factor in determining treatment outcome.
Although most patients included in the study contracted
malaria from the same area (i.e., Tak Province, Thai-
Myanmar border), parasite sensitivity to anti-malarials
can be strikingly different (Chaicharoenkul, unpublished
observation). In vitro sensitivity data indicate that there is
an intrinsically low sensitivity of P. falciparum isolates in
Thailand to fosmidomycin [20]. Unfortunately, in vitro
sensitivities of the parasite strains to fosmidomycin and
clindamycin were not investigated in either study. This
observation is supported by the pharmacokinetic data,
which clearly show the complete clearance of parasitae-
mia with no recrudescence during the 28- day follow up
period) in some individuals with comparable or even
lower trough plasma concentrations of fosmidomycin/
clindamycin when compared with those with recrudes-
cent parasitaemia. Minimising fluctuations between
trough and peak concentrations can be achieved by
administering the drugs more frequently at six hourly
intervals. Given the MIC data obtained for fosmidomycin
and clindamycin, it may be possible to simulate the
appropriate dose regimen for the combination despite the
lack in vitro sensitivity data.
Conclusion
The combination of fosmidomycin (900 mg) and clin-
damycin (300–600 mg) administered every six hours for
a minimum of five days would constitute the lowest dose
regimen with the shortest duration of treatment and
which could result in a cure rate greater than 95%. Com-
bination of fosmidomycin with another partner drug with
long half-life, e.g., azithromycin, may also be an alterna-
tive regimen for treatment of multidrug resistant falci-
parum malaria. Further study is required to prove this
supposition.
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